Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-25T20:13:11.167Z Has data issue: false hasContentIssue false

Comparative cannabis use data

Published online by Cambridge University Press:  02 January 2018

M. D. Abraham
Affiliation:
Centre for Drug Research, University of Amsterdam, Postbus 94208, 1090 GE Amsterdam, The Netherlands
P. D. A. Cohen
Affiliation:
Centre for Drug Research, University of Amsterdam, Postbus 94208, 1090 GE Amsterdam, The Netherlands
D. J. Beukenhorst
Affiliation:
Centraal Bureau voor de Statistiek (CBS), Heerlen, The Netherlands
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2001 

MacCoun & Reuter (2001) examine alternative legal regimes for controlling cannabis availability and use. They claim that the Dutch experience (the coffee shop system with decriminalisation of purchase, followed by “commercial promotion”) significantly increases cannabis use prevalence. They conclude, however, that primary harm comes more from criminalisation than from decriminalisation. They base their conclusions on the comparison of cannabis use data from The Netherlands and from other countries. Rightly, they warn that “ meaningful cross-sectional comparisons of drug use should be matched for survey year, measure of prevalence… and age groups covered in the estimate”. They forget that the comparisons should also be matched for type of geographical area. Comparing Flatbush to New York City would have limited relevance, even if correctly matched for age group etc. To compare cannabis use in New York City with somewhere else, one would have to look for a similar area, both in address density and in variation of population and lifestyle. Amsterdam could be compared to San Francisco, because these cities are very similar in size and cultural characteristics, but not to New York City, a metropolis over 10 times as large, or to the USA as a whole. Such comparisons are wrong and without meaning.

We agree with MacCoun & Reuter that decriminalising cannabis merits serious consideration. But we disagree with their observations on “ commercialisation”. In this letter we will turn most of our attention to the epidemiological material the authors base their conclusions on.

MacCoun & Reuter focus entirely on cannabis prevalence (assuming that a lower prevalence is better than a higher one) without considering whether this is the most relevant issue; the social and legal consequences of the use of cannabis could be considered at least as important. But given that a comparison of prevalence figures is a useful first step towards informed comparisons, we propose that the conclusion of MacCoun & Reuter that the commercial type of Dutch coffee shop system increases cannabis prevalence is based on statistically ill-founded comparisons of Dutch prevalence figures with those in other Western nations.

MacCoun & Reuter compare cannabis prevalence figures of a Dutch city or nationwide with prevalence figures from the USA or other Western nations. Differences are summed and averaged, resulting in (among others) a mean Dutch—US difference and a mean Dutch—European difference. This is statistically erroneous for reasons we supply below.

First, in 16 cases a Dutch city is compared with a nation (UK, USA, Sweden, etc). By doing this, MacCoun & Reuter presuppose that prevalence rates are the same all over The Netherlands. This is incorrect: in our 1997 national survey we found large geographical differences between locations with different address densities, a measure of urbanisation. For example, lifetime prevalence of cannabis use in Amsterdam (address density > 3000/km2) was 36.7%, the average national prevalence was 15.6% and average prevalence in rural areas (address density <500/km2) 10.5%. Correct international comparisons can be made, but have to be between comparable geographical or urban areas. Despite the sensitivity MacCoun & Reuter demand for correct comparisons, nationwide US figures (260 million inhabitants, including major metropolitan areas) are compared with the small Dutch city of Tilburg (165 000 inhabitants).

Second, comparisons are arbitrarily selected. For example, replacing prevalence figures for Amsterdam (the city most often chosen in MacCoun & Reuter's comparisons) with figures for Rotterdam changes the outcomes of the average difference in cannabis prevalence between the Dutch and other systems.

Third, MacCoun & Reuter state that the lifetime prevalence of cannabis in The Netherlands has increased consistently and sharply in the age group 18-20, stating: “the increases… provide the strongest evidence that the Dutch regime might have increased cannabis use among the young”. This finding is based on school survey data (lifetime cannabis use in 1984: 15%, in 1996: 44%). Again, the choice of figures that are compared is crucial. Moreover, the Dutch school survey data of the age group 18-20 is an extremely biased selection of this age cohort. The school survey takes place in some primary schools, but mostly in secondary educational institutions, that are designed for 12— to 18-year-olds. However, some persons remain much longer in this system for a variety of reasons but they are atypical for the age group in general. They bias the school survey estimate for this age group.

More suitable figures are given by Statistics Netherlands (CBS) and by the Centre for Drug Research (CEDRO), and reflect a much more moderate increase or no increase at all. Statistics Netherlands measures cannabis use prevalence in a national representative sample. For the age group 18-20 lifetime cannabis use remains at the same level over time (17% in 1989, 19% in 1990, 18% in 1991, 20% in 1992 and 14% in 1993; data from D. J. B.). Using CEDRO data, we are able to produce trend data for the city of Amsterdam for the same age group 18-20: in 1987 lifetime cannabis use was 34%, rising to 44% in 1997. This is a rather modest increase in cannabis use, very similar to the slowly rising consumption levels of other European and US measurements. The 18— to 20-year-olds in the samples from Amsterdam are randomly selected from the citizen registry, and represent the age group much better than 18— to 20-year-olds still attending school. The ‘dramatic’ increase that MacCoun & Reuter hypothesise in Dutch cannabis use in the period 1984-1996 (as reflected in the same age group) does not exist.

Finally, the most serious flaw develops by creating a series of ‘absolute’ differences between Dutch and other data, and averaging them. MacCoun & Reuter create the suggestion that too large or too small differences will be averaged and thereby, in the form of an ‘average’ difference, become more reliable. The opposite is true. If pears can not be compared to apples, their ‘differences’ can not be used for normal mathematical computations.

Footnotes

EDITED BY MATTHEW HOTOPF

References

Abraham, M. D., Cohen, P. D. A., van, Til R. J., et al (1999) Licit and Illicit Drug Use in The Netherlands. Amsterdam: Centre for Drug Research (CEDRO).Google Scholar
MacCoun, R. & Reuter, P. ( 2001) Evaluating alternative cannabis regimes. British Journal of Psychiatry, 178, 123-128.Google Scholar
Substance Abuse and Mental Health Services Administration (1997) National Household Survey on Drug Abuse: Population Estimates 1997. Rockville, MD: US Department of Health and Human Services.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.